Abstract
Drugs with high plasma protein binding are relatively protected from first-pass hepatic metabolism. However, there are concerns about potential problems caused by high plasma protein binding, one of which is toxicity. Statistical analyses of plasma concentration thresholds for toxic and comatose-lethal effects of drugs by multiple linear regression (MLR) models indicate that high plasma protein binding is slightly associated with toxicity of drugs in general, but not in the high (≥90%) plasma protein binding range. Lipophilicity as determined by the octanol/water partition coefficient (Log P) is a major driver of acute toxicity, which can largely and perhaps entirely explain the higher acute toxicity of drugs with high plasma protein binding. Neither plasma protein binding nor lipophilicity have any relation to the therapeutic window of drugs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Computational Biology and Drug Design
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
